abstract |
The present invention relates to the use of a combination of syrosingopine and a mitochondrial inhibitor (eg, metformin or oligomycin) and a combination of syrosingopine and a mitochondrial inhibitor to achieve cancer treatment and immunosuppression. The present invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of cancer cells. |